Search results
In the US, our portfolio of more than 280 medicines provides patients with more affordable access to quality medicines. Our growing Specialty portfolio meets important medical needs in neurology, endocrinology and other therapeutic categories.
Get the latest Amneal Pharmaceuticals Inc (AMRX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Mar 1, 2024 · Press Release Details. View All News. Amneal Reports Fourth Quarter and Full Year 2023 Financial Results. March 1, 2024. ‒ Full Year 2023 Performance Met or Exceeded Financial Guidance Metrics –. ‒ Q4 2023 Net Revenue of $617 million; GAAP Net Loss of $99 million; Diluted Loss per Share of $0.40 ‒. ‒ Q4 2023 Adjusted Net Income(1) of ...
Amneal Pharmaceuticals (NASDAQ:AMRX) shareholders are still up 235% over 1 year despite pulling back 8.0% in the past week Simply Wall St. • last month Amneal to Report First Quarter 2024 ...
Apr 24, 2024 · Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global pharmaceuticals company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 270 pharmaceutical products, primarily within the United States.
May 27, 2022 · BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s Biologics License Application (“BLA”) for pegfilgrastim-pbbk, a biosimilar referencing Neulasta ®. The product will be ...
Our broad portfolio of approximately 270 generic and specialty pharmaceuticals is the foundation from which we make healthy possible. And we expanded our portfolios to institutions, in biosimilars and across select international markets.
